Projects per year
Personal profile
Education
- 2002 Ph.D. National Taiwan University
- 1994 M.S. Taipei Medical University
Experience
- 2019- Director, Ph.D Program in Biotechnology Research and Development, Taipei Medical University
- 2018- Professor, Master Program in Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University
- 2016-2018 Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical University
- 2013-2016 Associate Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical University
- 2008-2013 Assistant Professor, Department of Pharmacology, Taipei Medical University
- 2009-2013 Assistant Investigator, National Health Research Institutes
- 2007-2009 Assistant Investigator, National Taiwan University
- 2002-2007 Postdoctor, National Taiwan Universiy
- 1994-1998 Teaching Assistant, Chang-Gung University
Research Interests
- Drug Discovery
- Disease animal model
- Pharmacology
URL
Fingerprint Dive into the research topics where Shiow-Lin Pan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 14 Similar Profiles
Apoptosis
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Histone Deacetylase Inhibitors
Medicine & Life Sciences
Cells
Chemical Compounds
Smooth Muscle Myocytes
Medicine & Life Sciences
Heterografts
Medicine & Life Sciences
Growth
Medicine & Life Sciences
Antineoplastic Agents
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2013 2019
- 12 Finished
新穎性選擇性HDAC抑制劑之抗癌藥物開發與藥理機轉探討(1/3)
8/1/18 → 7/31/19
Project: A - Government Institution › b - Ministry of Science and Technology
選擇性抗癌標靶藥物HDAC6抑制劑臨床前試驗研究
12/1/17 → 10/31/18
Project: A - Government Institution › b - Ministry of Science and Technology
選擇性HDAC1及2抑制劑作為新穎性抗癌藥物之藥物開發與藥理機轉探討
8/1/17 → 7/31/18
Project: A - Government Institution › b - Ministry of Science and Technology
新穎性pan-HDAC 抑制劑抑制血管新生之藥物研發與藥理作用機轉(3/3)
8/1/16 → 7/31/17
Project: A - Government Institution › b - Ministry of Science and Technology
Preclinical evaluation of novel selective HDAC6 inhibitors for human cancers treatment
1/1/16 → 12/31/16
Project: B - Project of TMU › h - Other (Funded by TMU)
Research Output 1996 2019
- 2866 Citations
- 32 h-Index
- 126 Article
Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cells
Nepali, K., Lin, M. H., Chao, M. W., Peng, S. J., Hsu, K. C., Eight Lin, T., Chen, M. C., Lai, M. J., Pan, S. L. & Liou, J. P., Oct 1 2019, In : Bioorganic Chemistry. 91, 103119.Research output: Contribution to journal › Article
Growth Inhibitors
Amides
Prostatic Neoplasms
Cells
Lead compounds
2
Citations
(Scopus)
Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo
Hsieh, Y. L., Tu, H. J., Pan, S. L., Liou, J. P. & Yang, C. R., Jun 1 2019, In : Biochimica et Biophysica Acta - Molecular Cell Research. 1866, 6, p. 992-1003 12 p.Research output: Contribution to journal › Article
Triple Negative Breast Neoplasms
Histone Deacetylase Inhibitors
Breast Neoplasms
Histone Deacetylases
Acetylation
Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. W., Chang, L. H., Tu, H. J., Chang, C. D., Lai, M. J., Chen, Y. Y., Liou, J. P., Teng, C. M. & Pan, S. L., May 29 2019, In : Clinical Epigenetics. 11, 1, 85.Research output: Contribution to journal › Article
Open Access
Histone Deacetylase Inhibitors
Mitogen-Activated Protein Kinase Kinases
Pancreatic Neoplasms
Epidermal Growth Factor Receptor
Heterografts
MPT0G413, A novel HDAC6-selective inhibitor, and bortezomib synergistically exert anti-tumor activity in multiple myeloma cells
Huang, F. I., Wu, Y. W., Sung, T. Y., Liou, J. P., Lin, M. H., Pan, S. L. & Yang, C. R., Jan 1 2019, In : Frontiers in Oncology. 9, APR, 249.Research output: Contribution to journal › Article
Open Access
Histone Deacetylases
Multiple Myeloma
Neoplasms
Histone Deacetylase Inhibitors
Growth
3
Citations
(Scopus)
1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC
Ojha, R., Huang, H. L., HuangFu, W. C., Wu, Y. W., Nepali, K., Lai, M. J., Su, C. J., Sung, T. Y., Chen, Y. L., Pan, S. L. & Liou, J. P., Apr 25 2018, In : European Journal of Medicinal Chemistry. 150, p. 667-677 11 p.Research output: Contribution to journal › Article
Hydroxamic Acids
Histone Deacetylase Inhibitors
Antineoplastic Agents
Protein Isoforms
Cells